Eiger BioPharmaceuticals (EIGR) Receives EMA Orphan Designation for Exendin 9-39 as NIPHS Treatment
Go back to Eiger BioPharmaceuticals (EIGR) Receives EMA Orphan Designation for Exendin 9-39 as NIPHS TreatmentEmpire Insurance Co (NASDAQ: EIGR) | Delayed: 1.73 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $1.73 | 52 Week High | $23.10 | |||
Open | $1.73 | 52 Week Low | $10.71 | |||
Day High | $1.73 | P/E | N/A | |||
Day Low | $1.73 | EPS | $0.00 | |||
Volume | 68,518 |